Effect of infliximab treatment on QT intervals in patients with ankylosing spondylitis.

• DOI: 10.2130/jim.0b013e3182330720
• Publication Date: 2011-12-01
• Authors: Soner Şenel; Veli Çobankara; Özgür Taşköylü; Aydın Güçlü; Harun Evrengül; Mehmet Güngör Kaya
• Keywords: Spondylitis

Cardiovascular complications are one of the most common and serious extraskeletal manifestations ankylosing spondylitis (AS). Infliximab, a monoclonal antibody against tumor necrosis factor, is widely used in treatment AS. QT dispersion (QTd), which relates to left ventricular function as an index cardiac dysrhythmia, may be useful prognostic guide. Early detection possible involvement not clinically evident, whereas it detected by electrocardiography.The aim this prospective study was assess effect infliximab on intervals patients with AS.Twenty-one (17 females 4 males) AS who were active phase disease (Bath Ankylosing Spondylitis Disease Activity Index score >4) enrolled study. Infliximab administered intravenously at dosage 5 mg/kg weeks 0, 2, 6 every thereafter. recorded before after months treatment.QT corrected (QTc) for heart rate significantly reduced therapy (406 ± 5.5 vs 388 6.6 milliseconds; P = 0.029). There no difference QTc (34.3 11.1 34.1 8.6; 0.171). Body mass lipid profile slightly increased treatment, but statistically insignificant.Inflammation can affect ventricles unknown mechanism, prolonged result In our study, shortened under suppressing inflammation. Therefore, protect from fatal arrhythmias sudden death.